|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003451,
umls-concept:C0019682,
umls-concept:C0028621,
umls-concept:C0030705,
umls-concept:C0030946,
umls-concept:C0036043,
umls-concept:C0132326,
umls-concept:C0243077,
umls-concept:C0332307,
umls-concept:C0439230,
umls-concept:C0441655,
umls-concept:C0939237
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-2-26
|
|
pubmed:abstractText |
The safety and antiviral activity of lopinavir (Lpv), a protease inhibitor (PI) coformulated with ritonavir (Rtv) to enhance its pharmacokinetic properties, were evaluated in 70 patients with plasma human immunodeficiency virus type 1 (HIV-1) RNA levels of 1000-100,000 copies/mL on a first PI-containing regimen. Patients were randomized to substitute only the PI with Lpv/Rtv, 400/100 mg or 400/200 mg twice daily. On day 15, nevirapine (200 mg 2x/day) was added, and nucleoside reverse-transcriptase inhibitors were changed. Despite a >4-fold reduction in phenotypic susceptibility to the preentry PI in 63% of patients, mean plasma HIV-1 RNA levels declined by 1.14 log(10) copies/mL after 2 weeks of Lpv/Rtv. At week 48, 86% of subjects receiving treatment had plasma HIV-1 RNA levels of <400 copies/mL; 76% had levels <50 HIV-1 RNA copies/mL (intent-to-treat: 70% and 60%, respectively). Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:BensonConstance ACA,
pubmed-author:BrunScott CSC,
pubmed-author:DeeksSteven GSG,
pubmed-author:EronJoseph JJJ,
pubmed-author:FeinbergJudithJ,
pubmed-author:GulickRoy MRM,
pubmed-author:HicksCharlesC,
pubmed-author:HsuAnnA,
pubmed-author:JapourAnthony JAJ,
pubmed-author:KempfDaleD,
pubmed-author:KesslerHarold AHA,
pubmed-author:KingMartinM,
pubmed-author:MurphyRobert LRL,
pubmed-author:RealKathrynK,
pubmed-author:RiddlerSharonS,
pubmed-author:SaxPaul EPE,
pubmed-author:StrykerRichardR,
pubmed-author:SunEugeneE,
pubmed-author:ThompsonMelanieM,
pubmed-author:WheelerDavidD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
185
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
599-607
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11865416-Adult,
pubmed-meshheading:11865416-Anti-HIV Agents,
pubmed-meshheading:11865416-CD4 Lymphocyte Count,
pubmed-meshheading:11865416-Double-Blind Method,
pubmed-meshheading:11865416-Drug Therapy, Combination,
pubmed-meshheading:11865416-Female,
pubmed-meshheading:11865416-HIV Infections,
pubmed-meshheading:11865416-HIV-1,
pubmed-meshheading:11865416-Humans,
pubmed-meshheading:11865416-Lopinavir,
pubmed-meshheading:11865416-Male,
pubmed-meshheading:11865416-Middle Aged,
pubmed-meshheading:11865416-Nevirapine,
pubmed-meshheading:11865416-Prospective Studies,
pubmed-meshheading:11865416-Pyrimidinones,
pubmed-meshheading:11865416-RNA, Viral,
pubmed-meshheading:11865416-Reverse Transcriptase Inhibitors,
pubmed-meshheading:11865416-Ritonavir,
pubmed-meshheading:11865416-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
|
|
pubmed:affiliation |
Department of Medicine, University of Colorado Health Sciences Center, 4200 E. 9th Avenue, B-168, Denver, CO 80262, USA. constance.benson@uchsc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
